Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome

Movement Disorders

Volumn 29, Issue 1, 2014, Pages 126-130

  Wijemanne, Subhashie ^a   Wu, Laura J C ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Fluphenazine; Side effects; Tardive dyskinesia; Tics; Tourette syndrome

Indexed keywords

FLUPHENAZINE; PROLACTIN;

ACUTE DYSTONIC REACTION; ADOLESCENT; ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; CHILD; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EMOTIONAL DISORDER; FATIGUE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MYOCLONUS; NAUSEA; NERVOUSNESS; OPTIMAL DRUG DOSE; PARKINSONISM; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALIVATION; SALIVATION DISORDER; SCHOOL CHILD; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; YOUNG ADULT;

FLUPHENAZINE; SIDE EFFECTS; TARDIVE DYSKINESIA; TICS; TOURETTE SYNDROME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DOPAMINE ANTAGONISTS; FEMALE; FLUPHENAZINE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOURETTE SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892938510     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25692     Document Type: Article

References (34)

1. Jankovic J. Tourette's syndrome. N Engl J Med 2001;345:1184-1192.
2. Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011;26:1149-1156.
3. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res 2008;65:461-472.
4. Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol 2012;8:203-213.
5. Seignot JN. A case of tic of Gilles de la Tourette cured by R 1625. [Article in French] Ann Med Psychol (Paris) 1961;119:578-579.
6. Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette's Syndrome with haloperidol. Br J Psychiatry 1968;114:345-350.
7. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154:1057-1062.
8. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-730.
9. Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette's syndrome. J Am Acad Child Psychiatry 1984;23:161-173.
10. Golden GS. Tardive dyskinesia in Tourette syndrome. Pediatr Neurol 1985;1:192-194.
11. Silva RR, Magee HJ, Friedhoff AJ. Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disorder. J Child Adolesc Psychopharmacol 1993;3:137-144.
12. Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 1983;11:205-208.
13. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985;12:71-74.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders TE, Revised (DSM-III-R). Washington, DC: American Psychiatric Association; 1987.
15. Group TTSCS. Definitions and classification of tic disorders. The Tourette Syndrome Classification Study Group. Arch Neurol 1993;50:1013-1016.
16. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol 1984;41:271-272.
17. Levinson DF, Simpson GM, Lo ES, et al. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 1995;152:765-771.
18. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
19. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-175.
20. Fahn S, Jankovic J, Hallett M. The tardive syndromes: phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes. In: Principles and Practice of Movement Disorders (Second Edition). Edinburgh: W.B. Saunders; 2011:415-446.
21. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937-941.
22. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254-258.
23. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003;64:1075-1080.
24. Muller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord 2011;26:2442-2443.
25. Singh SK, Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Mov Disord 1988;3:274-280.
26. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481.
27. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov 2013;3. Available at: http://tremorjournal.org/article/view/161.
28. Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010;10:893-901.
29. Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 1993;8:21-24.
30. Ayd FJ, Jr. Neuroleptics and extrapyramidal reactions in psychiatric patients. Rev Can Biol 1961;20:451-459.
31. Swett C, Jr. Drug-induced dystonia. Am J Psychiatry. 1975;132:532-534.
32. Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986;88:403-419.
33. Matar HE, Almerie MQ. Oral fluphenazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007;(1):CD006352.
34. Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011;26:147-152.